We are registered as an independent intermediary for medicines with the Dutch Ministry of Health
You can order Beleodaq (belinostat) via TheSocialMedwork if the drug has not been approved and/or is not available in the patient's country. TheSocialMedwork - helping patients and doctors access the latest approved medicines and at the lowest price possible worldwide.
Peripheral T-cell Lymphoma (PTCL)
Mode of Action
HDAC inhibitor (chemotherapy)
FDA approved (USA)
Who is belinostat for?
Belinostat is indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) .
Complete information about belinostat dosage and administration can be found here . The standard dosage is:
1,000 mg/m2 administered over 30 minutes by intravenous infusion once daily on days 1-5 of a 21-day cycle.
Cycles can be repeated until disease progression or unacceptable toxicity.
Treatment discontinuation or interruption with or without dosage reductions by 25 % may be needed to manage adverse reactions .
Consult your treating doctor for personalised dosing.
What is belinostat and how does it work?
Belinostat is a histone deacetylase (HDAC) inhibitor indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL), which shows preferential cytotoxicity towards tumour cells compared to normal cells .
Peripheral T-cell lymphoma are a group of T-cell lymphomas, blood cell tumours that affect T-cells, that develop away from the thymus. Several physiological and pathological cellular processes in the body are controlled by the balance between protein acetylation and deacetylation. Acetyltransferases (HATs) and deacetylases (HDACs) are enzymes involved in the maintenance of this equilibrium . A dysregulation of the HAT-HDAC balance has been well established as a significant event in lymphoma genesis . HATs is associated with gene transcription while HDAC activity is associated with gene silencing. Altered expression and mutations of genes that encode HDACs have been linked to tumour development since they induce the aberrant transcription of key genes regulating important cellular functions such as cell proliferation, cell-cycle regulation and apoptosis .
for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma.
The efficacy of belinostat for relapsed or refractory peripheral T-cell lymphoma was investigated in a multi-centre, single-arm trial of 120 patients with refractory or relapsed PTCL. Belinostat was administered by intravenous infusion at a dose of 1,000 mg/m2 once daily on days 1–5 of a 21 day cycle. The overall response rate (ORR) was 25.8 % (95 % CI (Confidence Interval): 18.3, 34.6). The overall complete and partial response rates were 10.8 % and 15.0 %, respectively. The median response duration (first date of response to disease progression or death) was 8.4 months (95 % CI: 4.5-29.4) .
The most common adverse reactions (>25 %) in the safety population (N=129) were nausea, fatigue, pyrexia, anemia, and vomiting. Thrombocytopenia was reported in 16 % of patients with grade 3 or 4 thrombocytopenia in 7 % of patients. Serious adverse reactions were reported in 47 % of patients. The most common serious adverse reactions (>2 %) were pneumonia, pyrexia, infection, anemia, increased creatinine, thrombocytopenia, and multi-organ failure. One treatment-related death due to hepatic failure was reported .
The European Medicines Agency (EMA) granted orphan designation for belinostat for the treatment of peripheral T-cell lymphoma  and malignant thymoma .
Buyer For EU individuals, VAT is 6% on medicines + 21% on shipping
Shipping Cost Estimate per order
VAT Tax can be claimed back by non-EU citizens on exiting the EU
Send this price estimate to your email address
Please complete the form, then try sending again.
*Once you provide us with the exact shipping address, the actual price may vary. After receiving the estimate, we may contact you to offer further assistance.
The more expensive medicines are patent-protected, and their prices are set by the pharmaceutical industry. We are constantly negotiating to get you best prices. As a social enterprise we only charge small fees to cover our operational costs.
Ordering with TheSocialMedwork is a safe and legal way to import a prescription medicine that has been approved in another country, but is not yet available where you live.
If you think that this medicine may be suitable for treating your condition, get in touch.
We'll answer any questions you might have and provide you with further information. Select the
Calculate Price tab to get a close estimate of the full cost of the medicine including delivery.
If you would like us to provide you with a precise quote we'll need to know the exact address of where you want us to send your medicine to.
2. Chat with your doctor
About whether this treatment might be suitable for you. In order to place an order with us, you’ll need to provide us with a prescription from your doctor who must be based in the same country where the medicine will be shipped to.
3. Place your order
Once you have your doctor's prescription you’re ready to place an order with us. Payment can be made by credit card, electronic bank transfer or Paypal.
As soon as we receive your payment we’ll process your order and your medicine will be shipped to you via a pharmacy.
Delivery time can vary from country to country but usually takes 1 to 3 weeks.
We'll send you a tracking number and keep you up to date on the status of your order.
Rest assured that we'll guide you through the entire process.
We'll let you know exactly what regulations need to be followed and the specific documentation you'll need to import the medicine into your country so that you get your treatment as quickly as possible. Ask us a question
"TheSocialMedwork helped us to get the medicine, which was not accessible for us, in the shortest possible time."
- Haoyu, China.
Registered with the Dutch Ministry of Health as an independent intermediary, Registration number 6730 BEM
Registered as a USA Delaware LLC.
DISCLAIMER: The Services of TheSocialMedwork do not replace a physician-patient relationship and are not intended as medical advice. TheSocialMedwork provides patients and physicians with existing treatment options abroad and creates access to these options after the patient and physician have made a professional decision.
Terms and Conditions